Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Telomir Pharmaceuticals, Inc.

NASDAQ: TELO · Life Sciences · 5 alerts · CIK 1971532

Share price
$0.4810Close, Nov 16
Market cap
$35.4M
Shares outstanding
73.68MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Telomir Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:41 PM ET 10-Q
Financial Results

Telomir Pharmaceuticals Q3 2026 Results: Net Loss of $705K, Loss Narrows

Telomir Pharmaceuticals reported a net loss of $3.42 million for the nine months ended September 30, 2026, a significant improvement from the $8.35 million loss in the prior year period. However, the net loss attributable to common stockholders surged to $49.53 million due to a $46.11 million deemed dividend, while cash reserves decreased to $4.52 million from $7.29 million at year-end 2025.

Key figure
Net loss $705K
8:01 AM ET 8-K
Capital Raise

Telomir Pharmaceuticals Capital Raise of $5.6M

Telomir Pharmaceuticals raised approximately $5.6 million in a PIPE financing through the issuance of 4,843,300 shares of common stock at $1.16 per share. The offering included a $1.0 million investment from existing shareholder John Paul DeJoria and will be used to fund the clinical development of Telomir-Zn for triple-negative breast cancer.

Value
$5.6M
Counterparty
John Paul DeJoria

“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir. Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”

John Paul DeJoria

“We have been very deliberate about how and when we access the capital markets. Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”

Erez Aminov, Chairman and CEO

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.